Protocol Ledger

NCT06082843 · Phase II · TERMINATED

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Interventional Phase II clinical trial protocol NCT06082843 sponsored by Boehringer Ingelheim in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-03 Enrollment: 22 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06082843
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)22 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06082843
Protocol FieldVerified Registry Value
NCT IdentifierNCT06082843
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment22 participants (ACTUAL)
Registered Start Date2024-01-03
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06082843
Hospital Research SiteLocationSite Profile
Universitätsklinikum MünsterMünster, GermanyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI